Literature DB >> 33126266

Induction of cell cycle arrest and apoptosis by CPUC002 through stabilization of p53 and suppression of STAT3 signaling pathway in multiple myeloma.

Yue Zhao1, Dongsheng Bai1, Jiaying Du1, Haochuan Ren1, Zhenguo Zhang2,3, Cheng Jiang4,5, Na Lu6.   

Abstract

Multiple myeloma has always been an important health problem in human beings due to its high morbidity, high mortality, and lack of effective therapeutic drugs. This study investigated the anticancer effect and mechanism of the newly synthesized small molecule compound CPUC002 on multiple myeloma. Our results confirmed that CPUC002 inhibited proliferation and induced G0/G1 cell cycle arrest in multiple myeloma cells. Moreover, CPUC002 also induced apoptosis by mitochondrial pathway and exogenous pathway. In mechanism, CPUC002 triggered apoptosis by stabilizing p53 in NCI-H929 cells which expressed wt-p53. Knockdown of p53 partially suppressed CPUC002-induced apoptosis. This suggests that there are other molecular mechanisms underlying CPUC002's antitumor effect. Further studies showed that the CPUC002 also inhibited the STAT3 signaling pathway, while knockdown of STAT3 abolished CPUC002-induced apoptosis and cell cycle arrest. In vivo, CPUC002 has significant antitumor activity through the same mechanism as our in vitro studies, and is highly safe in xenograft models. Together these findings indicate that CPUC002 induces apoptosis and G0/G1 cell cycle arrest in multiple myeloma cells by stabilizing p53 and inhibiting the STAT3 signaling pathway.

Entities:  

Keywords:  Apoptosis; CPUC002; Multiple myeloma; STAT3; p53

Mesh:

Substances:

Year:  2020        PMID: 33126266     DOI: 10.1007/s10565-020-09565-x

Source DB:  PubMed          Journal:  Cell Biol Toxicol        ISSN: 0742-2091            Impact factor:   6.691


  34 in total

1.  Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome.

Authors:  Hervé Avet-Loiseau; Michel Attal; Philippe Moreau; Catherine Charbonnel; Frédéric Garban; Cyrille Hulin; Serge Leyvraz; Mauricette Michallet; Ibrahim Yakoub-Agha; Laurent Garderet; Gérald Marit; Lucienne Michaux; Laurent Voillat; Marc Renaud; Bernard Grosbois; Gaelle Guillerm; Lotfi Benboubker; Mathieu Monconduit; Catherine Thieblemont; Philippe Casassus; Denis Caillot; Anne-Marie Stoppa; Jean-Jacques Sotto; Marc Wetterwald; Charles Dumontet; Jean-Gabriel Fuzibet; Isabelle Azais; Véronique Dorvaux; Marc Zandecki; Régis Bataille; Stéphane Minvielle; Jean-Luc Harousseau; Thierry Facon; Claire Mathiot
Journal:  Blood       Date:  2007-01-05       Impact factor: 22.113

2.  In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells.

Authors:  Dharminder Chauhan; Ze Tian; Bin Zhou; Deborah Kuhn; Robert Orlowski; Noopur Raje; Paul Richardson; Kenneth C Anderson
Journal:  Clin Cancer Res       Date:  2011-06-30       Impact factor: 12.531

3.  A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6.

Authors:  Linda B Baughn; Maurizio Di Liberto; Kaida Wu; Peter L Toogood; Tracey Louie; Rachel Gottschalk; Ruben Niesvizky; Hearn Cho; Scott Ely; Malcolm A S Moore; Selina Chen-Kiang
Journal:  Cancer Res       Date:  2006-08-01       Impact factor: 12.701

Review 4.  Cell Cycle Regulation in Treatment of Breast Cancer.

Authors:  Zijie Cai; Qiang Liu
Journal:  Adv Exp Med Biol       Date:  2017       Impact factor: 2.622

5.  Mitochondrial MDM2 Regulates Respiratory Complex I Activity Independently of p53.

Authors:  Giuseppe Arena; Madi Yann Cissé; Samuel Pyrdziak; Laurent Chatre; Romain Riscal; Maryse Fuentes; Jamie Jon Arnold; Markus Kastner; Laurie Gayte; Christelle Bertrand-Gaday; Kevin Nay; Claire Angebault-Prouteau; Kerren Murray; Beatrice Chabi; Christelle Koechlin-Ramonatxo; Béatrice Orsetti; Charles Vincent; François Casas; Jean-Christophe Marine; Sandrine Etienne-Manneville; Florence Bernex; Anne Lombès; Craig Eugene Cameron; Hervé Dubouchaud; Miria Ricchetti; Laetitia Karine Linares; Laurent Le Cam
Journal:  Mol Cell       Date:  2018-02-15       Impact factor: 17.970

6.  Dual inactivation of Akt and ERK by TIC10 signals Foxo3a nuclear translocation, TRAIL gene induction, and potent antitumor effects.

Authors:  Joshua E Allen; Gabriel Krigsfeld; Patrick A Mayes; Luv Patel; David T Dicker; Akshal S Patel; Nathan G Dolloff; Evangelos Messaris; Kimberly A Scata; Wenge Wang; Jun-Ying Zhou; Gen Sheng Wu; Wafik S El-Deiry
Journal:  Sci Transl Med       Date:  2013-02-06       Impact factor: 17.956

Review 7.  Targeting mutant p53 for efficient cancer therapy.

Authors:  Vladimir J N Bykov; Sofi E Eriksson; Julie Bianchi; Klas G Wiman
Journal:  Nat Rev Cancer       Date:  2017-12-15       Impact factor: 60.716

8.  Identification of TRAIL-inducing compounds highlights small molecule ONC201/TIC10 as a unique anti-cancer agent that activates the TRAIL pathway.

Authors:  Joshua E Allen; Gabriel Krigsfeld; Luv Patel; Patrick A Mayes; David T Dicker; Gen Sheng Wu; Wafik S El-Deiry
Journal:  Mol Cancer       Date:  2015-05-01       Impact factor: 27.401

Review 9.  STATs: An Old Story, Yet Mesmerizing.

Authors:  Saeid Abroun; Najmaldin Saki; Mohammad Ahmadvand; Farahnaz Asghari; Fatemeh Salari; Fakher Rahim
Journal:  Cell J       Date:  2015-10-07       Impact factor: 2.479

10.  STAT3 Target Genes Relevant to Human Cancers.

Authors:  Richard L Carpenter; Hui-Wen Lo
Journal:  Cancers (Basel)       Date:  2014-04-16       Impact factor: 6.639

View more
  2 in total

1.  METTL3 facilitates multiple myeloma tumorigenesis by enhancing YY1 stability and pri-microRNA-27 maturation in m6A-dependent manner.

Authors:  Feifei Che; Xuemei Ye; Yu Wang; Xuemei Wang; Shuyue Ma; Yawen Tan; Yan Mao; Ziyue Luo
Journal:  Cell Biol Toxicol       Date:  2022-01-17       Impact factor: 6.691

2.  A Novel Isaindigotone Derivative Displays Better Anti-Proliferation Activities and Induces Apoptosis in Gastric Cancer Cells.

Authors:  Kangjia Du; Chengjie Yang; Zhongkun Zhou; Yunhao Ma; Yanan Tian; Rentao Zhang; Hao Zhang; Xinrong Jiang; Hongmei Zhu; Huanxiang Liu; Peng Chen; Yingqian Liu
Journal:  Int J Mol Sci       Date:  2022-07-21       Impact factor: 6.208

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.